Realizing the Potential of CDK 4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: Managed Care Considerations on Recent Evidence in Real-World Practice

Realizing the Potential of CDK 4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: Managed Care Considerations on Recent Evidence in Real-World Practice is organized by National Association of Managed Care Physicians (NAMCP) and will be held from Jan 01, 2022 - Jan 01, 2024.,,Description:,Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. The incidence in women in the United States is 1 in 8 (about 13 percent). About 43,600 women are expected to die from breast cancer this year, though death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced, metastatic setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Fortunately for advanced breast cancer patients with HR+/HER2- advanced breast cancer, several new agents, including CDK 4/6 inhibitors, have changed the paradigm in the last 10 years, and recent real-world data has been released that shows the strong efficacy and safety of these options. With this new data becoming available, it is imperative to provide medical directors, oncologists, pharmacy directors, oncology case managers and others on the interprofessional management team with this new data and best practices on the evolving treatment paradigm, with the ultimate goal of optimizing access and improving outcomes for patients who would benefit from these options.,,A Closer Look at Recent Real-World and Clinical Trial Data in the Management of HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on the Evolving Role of CDK 4/6 Inhibitors:,• Examine the unmet clinical needs in HR+/HER2- metastatic breast cancer and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity,• Analyze recent efficacy and safety data on CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer,• Explore real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer,• Evaluate best practices for analyzing, interpreting and utilizing real-world data in addition to data collected from clinical trials related to CDK 4/6 inhibitors in metastatic breast cancer in terms of study design, validity, data sources, and implications for everyday managed care and oncology practice,• Compare and contrast adverse events associated with CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer in order to improve patient adherence and quality of life, ,,What Managed Care Needs to Know About Recent Real-World Evidence and Best Practices for CDK 4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: Utilizing Recent Data for Optimal Decision Making:,• Examine the unmet economic needs in HR+/HER2- metastatic breast cancer and the impact of inadequately treated disease on physical and mental health, quality of life, costs and work productivity,• Explore real-world evidence derived from real-world data supplementing clinical trial evidence related to the benefits and risks of CDK 4/6 inhibitors in HR+/HER2- metastatic breast cancer,• Formulate recommendations to ensure appropriate access for first-line treatment of HR+/HER2- metastatic breast cancer with CDK 4/6 inhibitors,• Assess the managed care considerations of CDK 4/6 inhibitors by exploring where these agents fit into current metastatic breast cancer management paradigm,• Transform therapeutic advances and resource utilization data on emerging therapies in alopecia areata into informed health plan decisions and formulary discussions